Diabetes Drug Tirzepatide Cuts Alcohol Cravings by 50% in Lab Tests

A new study suggests that tirzepatide, a drug already used for diabetes, could help treat alcohol dependence. Researchers at the University of Gothenburg found it drastically cut alcohol intake in animal tests. The findings point to a potential breakthrough in addiction treatment, though human trials have yet to begin.

The study showed that tirzepatide reduced voluntary alcohol consumption in animals by over 50%. Episodes of binge drinking also dropped sharply. Unlike existing treatments, the drug works by altering the brain's reward system, weakening dopamine responses linked to alcohol cravings.

Tirzepatide acts on two key receptors—GIP and GLP-1—which may give it an edge over similar medications like semaglutide. Early evidence suggests it could even trigger lasting biological changes in the brain, possibly through epigenetic effects. This might help sustain long-term reductions in addictive behavior.

Despite promising results, no clinical trials for alcohol dependence have been submitted to regulators like the EMA or FDA. Since tirzepatide is already approved for diabetes, however, future trials could move faster than usual.

The drug's ability to curb alcohol use in animals offers hope for a new addiction therapy. But further human studies are required before it can be considered for approval. If successful, tirzepatide may provide a more effective alternative to current treatments for alcohol dependence.